Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 364,670
  • Shares Outstanding, K 759,729
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,490 K
  • 60-Month Beta -0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.01
Trade CYBN.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.09 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4600 +1.09%
on 04/25/24
0.6400 -27.34%
on 04/03/24
-0.1050 (-18.42%)
since 03/25/24
3-Month
0.3700 +25.68%
on 02/07/24
0.7400 -37.16%
on 03/13/24
-0.0100 (-2.11%)
since 01/25/24
52-Week
0.3000 +55.00%
on 06/13/23
1.0200 -54.41%
on 10/31/23
+0.0350 (+8.14%)
since 04/25/23

Most Recent Stories

More News
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.4650 (-3.12%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3430 (-3.38%)
ATAI : 1.8300 (-2.14%)
MNMD : 8.49 (+0.35%)
SEEL : 0.2862 (-4.92%)
CMPS : 7.83 (-3.33%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 0.3430 (-3.38%)
CYBN.NE : 0.4650 (-3.12%)
Cybin to Acquire Small Pharma Inc.

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders...

DMTTF : 0.1117 (-9.70%)
DMT.VN : 0.150 (-6.25%)
CYBN.NE : 0.4650 (-3.12%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.4650 (-3.12%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3430 (-3.38%)
CMPS : 7.83 (-3.33%)
SEEL : 0.2862 (-4.92%)
MNMD : 8.49 (+0.35%)
NUMIF : 0.0575 (-3.36%)
NUMI.TO : 0.0750 (-6.25%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference;...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced significant progress...

CYBN.NE : 0.4650 (-3.12%)
CYBN : 0.3430 (-3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various...

See More

Key Turning Points

3rd Resistance Point 0.5333
2nd Resistance Point 0.5167
1st Resistance Point 0.4983
Last Price 0.4650
1st Support Level 0.4633
2nd Support Level 0.4467
3rd Support Level 0.4283

See More

52-Week High 1.0200
Fibonacci 61.8% 0.7450
Fibonacci 50% 0.6600
Fibonacci 38.2% 0.5750
Last Price 0.4650
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar